CVS Health, the nation’s second largest pharmacy chain and one of the largest health care companies in the U.S., recently announced that it will no longer sell decongestants containing the ingredient phenylephrine. The decision follows a growing number of studies linking the ingredient to serious side effects.
Phenylephrine is a common active ingredient found in many over-the-counter cold and flu medications. It is widely used to relieve nasal congestion, but research has linked it to a number of serious side effects, including heart palpitations, hypertension, and increased risk of stroke.
Other studies have suggested that long-term use of medications containing phenylephrine can lead to weight gain, anxiety, and insomnia.
CVS Health’s decision to stop selling products containing phenylephrine is a major step forward in the consumer health industry. The company noted that its decision is meant to safeguard customers and ensure their safety. CVS Health announced it will phase out products containing phenylephrine within the next 90 days, and will instead focus on alternatives, such as nasal sprays and oral medications.
As a leading pharmacy chain in the United States, CVS Health’s decision has the potential to spur a wave of similar changes in the industry. The company is also hoping to set an example for other retailers, which will hopefully follow suit and take steps to remove products containing phenylephrine from their shelves.
CVS Health’s move to stop selling products with phenylephrine is a welcome development for many consumers who were unaware of the serious side effects linked to the ingredient. With the company’s decision, customers can rest assured that they are making safe buying decisions and taking control of their health.